Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.

Yoichi Nakanishi, Koichi Takayama, Hiroshi Wataya, Miiru Izumi, Takahiro Minami, Koichi Takano, Koji Inoue, Shin'ichi Osaki, Kanehito Kimotsuki, Taishi Harada, Nobuyuki Hara

研究成果: Contribution to journalArticle

4 被引用数 (Scopus)

抄録

BACKGROUND: Previous studies have reported a synergistic effect between irinotecan and cisplatin. We have conducted a phase I trial combining these agents to find the optimal dose of irinotecan in combination with a fixed dose of cisplatin. METHODS: Patients with advanced solid tumors, aged < or =75 years, performance status < or =2, and adequate organ function were enrolled in this study. They were treated at 4-week intervals with irinotecan plus 20 mg/m(2) cisplatin on days 1, 8, and 15. The starting dose of irinotecan of 40 mg/m(2) was escalated in 10 mg/m(2) increments until a maximum dose of 90 mg/m(2) was reached. RESULTS: The recommended dose for phase II studies is 90 mg/m(2) of irinotecan and 20 mg/m(2) of cisplatin on days 1, 8, and 15. Overall response to the chemotherapy was 35% (95% confidential interval, 19.2-54.6%). CONCLUSION: This combination seems to be active against lung cancer with acceptable toxicity. A phase II study is now ongoing.

本文言語英語
ページ(範囲)205-210
ページ数6
ジャーナルCHEMOTHERAPY
48
4
DOI
出版ステータス出版済み - 9 2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

フィンガープリント 「Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル